The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 agonist that’s exhibiting significant promise in clinical trials for addressing obesity. Unlike some current weight loss solutions, retatrutide appears to offer a more substantial decrease in body weight and improve metabolic health,